Related Experiment Video
Updated: Jul 9, 2025
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Disulfidptosis-related PABPC3 promotes tumor progression and inhibits immune activity in osteosarcoma
Yangbo Cao1, Song Wu1, Yishan Gu2
1Department of Orthopaedics, The Third Xiangya Hospital, Central South University, Changsha, China.
Background:
Osteosarcoma is a very aggressive bone tumor mainly affecting teens and young adults. Disulfidptosis is a metabolic-related form of regulated cell death. However, the interconnection between disulfidptosis and osteosarcoma has not been explored.
Methods:
In the present study, disulfidptosis-related clusters were identified in osteosarcoma using the nonnegative matrix factorization clustering method. PABPC3 was identified as a hazardous gene in osteosarcoma using machine learning algorithms, CoxBoost, and Random Survival Forest. The prognostic value, pathway annotation, immune characteristics, and drug prediction of PABPC3 were systematically explored. MTT (i.e., 3-(4, 5-dimethyl thiazol-2-yl)-2,5-diphenytetrazolium bromide), EdU (ie. 5-ethyny-2'-deoxvuridine), and Transwell assays were used for in vitro validation of PABPC3.
Results:
The disulfidptosis-related clusters could distinguish survival outcomes of osteosarcoma patients. PABPC3 could predict survival outcomes, immune activity, and drug response in osteosarcoma patients. Besides, PABPC3 was proven to facilitate the proliferation and migration of osteosarcoma.
Conclusions:
The present study is expected to establish the bridge between disulfidptosis and osteosarcoma. PABPC3 is expected to be further explored as a therapeutic target in osteosarcoma.
Insights
Disulfidptosis, a cell death process, is linked to osteosarcoma, a bone cancer. The gene PABPC3 shows potential as a prognostic and therapeutic target for osteosarcoma patients.
Area of Science:
- Oncology
- Cell Biology
- Genetics
Background:
- Osteosarcoma is an aggressive bone tumor primarily affecting adolescents and young adults.
- Disulfidptosis is a metabolic-related programmed cell death pathway.
- The relationship between disulfidptosis and osteosarcoma remains largely unexplored.
Purpose of the Study:
- To investigate the role of disulfidptosis in osteosarcoma.
- To identify potential biomarkers and therapeutic targets for osteosarcoma.
- To explore the prognostic value of PABPC3 in osteosarcoma.
Main Methods:
- Nonnegative matrix factorization was used to identify disulfidptosis-related clusters in osteosarcoma.
- Machine learning algorithms (CoxBoost, Random Survival Forest) identified PABPC3 as a risk gene.
- In vitro assays (MTT, EdU, Transwell) validated PABPC3's function.
Main Results:
- Disulfidptosis-related clusters effectively differentiated osteosarcoma patient survival outcomes.
- PABPC3 demonstrated prognostic value, predicting survival, immune activity, and drug response.
- PABPC3 was found to promote osteosarcoma cell proliferation and migration.
Conclusions:
- This study establishes a link between disulfidptosis and osteosarcoma.
- PABPC3 is a potential therapeutic target for osteosarcoma treatment.
- Further research into PABPC3's role in osteosarcoma is warranted.
